Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Neumora (NMRA) Q2 Loss Improves 10%
07:46pm, Wednesday, 06'th Aug 2025
Neumora Therapeutics (NMRA -4.22%), a clinical-stage neuroscience company developing targeted therapies for brain diseases, released its second quarter 2025 results on August 6, 2025. The most signifi
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 06'th Aug 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioriti
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
07:00am, Wednesday, 23'rd Jul 2025
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
07:00am, Wednesday, 09'th Jul 2025
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted in multiple species, including rabbit
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
09:40pm, Tuesday, 27'th May 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) brea
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm
03:50pm, Wednesday, 14'th May 2025
NEW YORK , May 14, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breac
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
07:18pm, Monday, 12'th May 2025
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q1 2025 Results Conference Call May 12, 2025 4:30 PM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Ber
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
04:01pm, Monday, 12'th May 2025
On track to report topline data from NMRA-511 in Alzheimer's disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
07:00am, Monday, 28'th Apr 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain diseas
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumor
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline
04:15pm, Monday, 07'th Apr 2025
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secur
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been fil
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal secur
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
12:32pm, Monday, 07'th Apr 2025
LOS ANGELES--(BUSINESS WIRE)--NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
